Navigation Links
Hepregen Corporation Receives SBIR Phase II Grant from the National Science Foundation and Presents Corporate Update at OneMed Forum

New Grant Adds to Hepregen’s Previous NIH Funding and Continued Development of the Company’s Platform for Advanced Toxicity Screening and Drug Discovery

San Francisco, CA and Medford, MA (Vocus) January 13, 2010 -- Hepregen Corporation, a leading provider of bioengineered solutions for drug development, announced today that it has received a Phase II SBIR grant from the National Science Foundation for $500,000. This latest award, in addition to the company’s receipt of a prestigious Challenge Grant from the National Institutes of Health (NIH), along with earlier grant awards, approaches $2.0M in federal funding.

Hepregen will also be a featured speaker this afternoon at OneMedForum, where CEO Bernadette (Bonnie) Fendrock will highlight the company’s successful progress since its Series A financing in 2008 from Battelle Ventures, as well as outline important milestones for 2010 and beyond.

The SBIR Phase II grant received from the National Science Foundation will support Hepregen’s project, "Development of a Human Liver Platform for High-Throughput Screening of Drug-Induced Liver Injury and Drug-Drug Interaction.” The project is currently being lead by Dr. Salman Khetani, co-developer of Hepregen’s platform technology and also Director of Research at the company. The grant, which initiates on January 15, 2010, as well as the previous Challenge grant from the NIH, will be contributors to the company’s growth as Hepregen continues to develop its proprietary HepatoPaC™ technology.    

Hepregen President and CEO Bonnie Fendrock, who cofounded the company, commented, “2009 was an exciting year at the company. With the Series A financing from Battelle Ventures in combination with our grant funding, Hepregen was able to execute on its business plan. Liver toxicity is a leading cause of preclinical failures of drugs, and we are working to validate that the unique HepatoPaC™ platform will enable pharmaceutical companies to improve predictivity, thereby reducing costs and clinical risks.”

Eighty percent of all drugs are metabolized or detoxified in the liver; therefore, the safety of drugs as they travel through the liver is of prime importance to the pharmaceutical industry. Hepregen is developing a unique, bioengineered microliver platform as a highly functional model of the liver in vivo. The potential of Hepregen’s HepatoPaCTM platform is to provide higher content data for faster, more-informed decision making, while offering significant value for the pharmaceutical industry.

CEO Bonnie Fendrock will be a featured speaker at the OneMedForum conference taking place on January 13-15, 2010 in San Francisco, CA. Ms. Fendrock will provide an overview of the company’s technology platform, update on company progress and key milestones for 2010.

Who: Bernadette C. Fendrock (Bonnie), President and CEO
What: OneMed Forum 2010 Emerging Company Finance Conference
Where: Sir Francis Drake Hotel, San Francisco, CA 94102
When: Wednesday, January 13, 2010 at 1:50 p.m. PST

About Hepregen Corporation
Hepregen’s mission is to translate the value of its technology platform to improve the safety and efficacy of drugs in development with greater economic efficiency and significant impact on patients’ lives. The company is focused on advancing and commercializing its microliver platform, HepatoPaCTM, into the drug-development pipeline of pharmaceutical and biotechnology companies. Hepregen’s platform technology offers the potential to deliver a breakthrough technology for toxicity screening and a new platform for drug discovery. It combines sophisticated biological and engineering technologies to create an in vitro liver model which closely mimics many key functions of the human liver. In 2008, Battelle Ventures spun out Hepregen Corporation from the Massachusetts Institute of Technology (MIT), and led the company’s Series A financing. For more information about Hepregen, please visit:

Lisa Rivero                            
LaVoie Group
Office: 978-745-4200 x106


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. United American Healthcare Corporation Announces Meeting Date and Record Date for Annual Meeting of Shareholders
2. Amerigroup Corporation to Discuss Fourth Quarter and 2009 Year-End Earnings on February 19
3. Providence Service Corporation Comments on Senate Health Care Reform
4. Triple-S Management Corporation to Present at J. P. Morgan Healthcare Conference
5. Service Corporation International Extends Offer for Keystone North America Inc.
6. Atrion Networking Corporation Selects Ruckus Wireless for Reliable as Wire Enterprise Wi-Fi Service
7. Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees Benefit Selection Process
8. China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009
9. New Board Gains Control of U.S. Shanghai Chemical Corporation
10. Centene Corporation to Provide 2010 Financial Guidance On January 8, 2010
11. American Diversified Holdings Corporation Announces Stem Cell Patent Acquisition Program
Post Your Comments:
Related Image:
Hepregen Corporation Receives SBIR Phase II Grant from the National Science Foundation and Presents Corporate Update  at OneMed Forum
(Date:12/1/2015)... ... December 02, 2015 , ... ... events and association with initiation of treatment for osteoporosis ”. , As corresponding ... pharmacological treatment in patients diagnosed with osteoporosis. Based on a large US managed ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an article published ... discrimination claim against the U.S. Department of Health and Human Services, claiming that any ... plans are breaking the clause in the law prohibiting the denial of coverage for ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of ... has been named by MedEsthetics magazine as the Best Single Physician Practice in the ... the many elite aesthetic physicians honored by the industry publication. , Dr. Vitenas ...
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... in the 1980s we have seen vast improvements in scientific research and discoveries, ... significant strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic ... United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a ... catastrophic contributors to diseases of the diabetic foot. The American Board of ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Dec. 1, 2015 Array BioPharma ... that its Chief Executive Officer, Ron ... Annual Healthcare Conference in New York.  The ... conference through a webcast on the Array ... , --> , ...
(Date:12/1/2015)... Dec. 1, 2015 Assurex Health, Inc. ... test giving healthcare providers an expanded range of ... patients suffering from depression, anxiety, bipolar disorder, posttraumatic ... conditions. i .   ... With the addition of two new drug classes, ...
(Date:12/1/2015)... 1, 2015 --> ... report "Nucleic Acid Labeling Market by Product (Reagents & ... Primer, In Vitro Transcription, Reverse Transcription, End Labeling), by ... The global market is expected to reach USD 1,925.7 ... growing at a CAGR of 8.65%. Browse ...
Breaking Medicine Technology: